<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00396084</url>
  </required_header>
  <id_info>
    <org_study_id>01-553</org_study_id>
    <secondary_id>TBRU 10</secondary_id>
    <nct_id>NCT00396084</nct_id>
  </id_info>
  <brief_title>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</brief_title>
  <official_title>Randomized, Open Label, Multiple Dose Phase I Study of the Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, and Moxifloxacin in HIV-non-infected Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      This study will evaluate the ability of 4 antibiotics to kill the bacteria that cause
      tuberculosis (TB). The antibiotics to be studied are linezolid, gatifloxacin, levofloxacin,
      and moxifloxacin. All are approved by the Brazilian health authorities to treat infections
      caused by germs other than TB. Seventy human immunodeficiency virus (HIV)-negative adults,
      aged 18-65 years, who have been newly diagnosed with pulmonary (lung) TB, will participate in
      this study. Study volunteers will be given one of the 4 study drugs or a comparison
      antibiotic, Isoniazid, which has been used around the world as a standard of care treatment
      for TB. Volunteers will stay in the hospital for 10 days and be given a study antibiotic 7 of
      those days. Blood and saliva samples will be taken. Six weeks later, volunteers will return
      for a final health check. All volunteers will receive 6 months of standard tuberculosis
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-drug resistant tuberculosis now affects all regions of the world and is a significant
      concern for national tuberculosis (TB) control programs. The development and testing of new
      drugs and new classes of drugs and immunotherapeutic agents are vital elements in the global
      response to this challenge. The fluoroquinolones and oxazolidinones represent two promising
      classes of drugs that show activity against Mycobacterium tuberculosis (MTB). This study is a
      randomized, open label, multiple dose phase I clinical trial to evaluate the early
      bactericidal activity (EBA) of gatifloxacin, levofloxacin, moxifloxacin, and linezolid
      compared with an isoniazid (INH) control arm in patients with newly-diagnosed sputum
      smear-positive pulmonary tuberculosis (TB). Secondary study objectives are to: compare
      results of sputum MTB messenger ribonucleic acid (mRNA) clearance with results of a standard
      EBA study [change in sputum viable counts [colony forming units (CFU)]; compare the rate of
      clearance of sputum cytokine proteins with results of a standard EBA assay CFU; determine the
      pharmacokinetics (PK) of the study drugs in patients with smear-positive pulmonary TB; and
      demonstrate that lack of EBA activity is not due to low serum drug concentrations. Seventy
      human immunodeficiency virus (HIV) negative adults, aged 18-65 years, who have been newly
      diagnosed with pulmonary TB, will be enrolled and admitted to the Centro de Pesquisa
      (Clinical Research Ward) at the Hospital Universitario Cassiano Antonio de Moraes of the
      Universidade Federal do Espírito Santo in Vitória. The subjects will be randomized to receive
      gatifloxacin, levofloxacin, moxifloxacin, or INH (control), and after these arms are
      enrolled, they will be randomized to receive either linezolid (600 mg once daily) or
      linezolid (600 mg twice daily) or INH (control). During the inpatient stay, study drugs will
      be given for 7 days following a 2-day drug-free period when baseline sputum bacillary counts
      will be measured. The 7-day duration of the study drug phase will allow measurement of sputum
      bactericidal activity both during the first 2 days of study drug administration and between
      days 2 and 7 of study drug administration to gain additional information on the possible
      sterilizing activity of the drugs. The extended nature of these EBA studies will allow
      assessment of this possibility in the study drugs that would be missed if a shorter EBA study
      was performed. Sputum specimens will be collected for 2 days prior to initiation of study
      drug in order to establish a baseline quantitative culture result and then specimens will be
      collected daily thereafter. Sputum specimens will be processed to evaluate changes in
      mycobacterial mRNA/proteins and cytokine proteins. PK studies will be performed after 5 days
      of study drug administration (Day 5). Safety evaluations including clinical examination,
      complete blood counts, and serum total bilirubin, aspartate aminotransferase (AST),
      creatinine, and urinalysis will be followed to monitor for drug toxicity. Drug susceptibility
      testing will be performed on an initial sputum isolate and will be repeated after completion
      of 7 days of study drugs, and on isolates from patients with positive sputum cultures at the
      day 42 study visit to assess for the development of acquired drug resistance. Isolates will
      be tested against INH, rifampicin, pyrazinamide, ethambutol and the subject's assigned study
      drug. Patients who are found to be resistant to their assigned study drug at baseline will
      not be analyzable. After the initial treatment, all subjects will receive 6 months of
      standard TB treatment outside of the hospital.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC)</measure>
    <time_frame>Study drug administration duration - 7 days monotherapy</time_frame>
    <description>The adjusted area under the curve (aAUC) for sputum colony forming units (cfu) for each day on treatment was calculated. The aAUC represents the percentage of the expected AUC given no change in log cfu in response to study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Sputum Bacillary Loads: Early Bactericidal Activity (EBA) Days 0 to 2; Fluoroquinolones/Isoniazid (INH) Comparison</measure>
    <time_frame>Day 0 to Day 2 Monotherapy</time_frame>
    <description>Early bactericidal activity (EBA 0-2) was calculated as the rate of fall in sputum colony forming units (cfu) (expressed in log10 units) during the first 2 days of monotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extended Early Bactericidal Activity (EBA) From Days 2 to 7; Fluoroquinolones/Isoniazid (INH) Comparison</measure>
    <time_frame>Day 2 to Day 7 Monotherapy</time_frame>
    <description>The rate of fall in sputum cfu between day 2 and day 7 of monotherapy was estimated by the slope of the linear regression obtained by fitting the 6 sputum cfu values corresponding to Days 2 through 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC)</measure>
    <time_frame>Study drug administration duration - 7 days monotherapy</time_frame>
    <description>The adjusted area under the curve (aAUC) for sputum colony forming unit (cfu) for each day on treatment was calculated for patients in the INH arm and those in the Linezolid once daily and Linezolid twice daily arms. The aAUC represents the percentage of the expected AUC given no change in log cfu in response to study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Sputum Bacillary Loads: Early Bactericidal Activity (EBA) Days 0 to 2; Linezolid Once Daily/Linezolid Twice Daily/Isoniazid (INH) Comparison</measure>
    <time_frame>Day 0 to Day 2 Monotherapy</time_frame>
    <description>Early bactericidal activity (EBA 0-2) was calculated as the rate of fall in sputum cfu (expressed in log10 units) during the first 2 days of monotherapy. Mean values for the 3 treatment groups were compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Sputum Bacillary Loads: Extended Early Bactericidal Activity (EBA) From Days 2 to 7; Linezolid Once Daily/Linezolid Twice Daily/INH Comparison</measure>
    <time_frame>Day 2 to Day 7 Monotherapy</time_frame>
    <description>The rate of fall in sputum cfu between day 2 and day 7 of monotherapy was estimated by the slope of the linear regression obtained by fitting the 6 sputum cfu values corresponding to Days 2 through 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sputum mRNA Clearance Rate - Results Are Pending.</measure>
    <time_frame>Study drug administration duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Cytokine Proteins - Results Are Pending.</measure>
    <time_frame>Study drug administration duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Drug Concentration (Cmax)</measure>
    <time_frame>Day 5 (7 time points)</time_frame>
    <description>Maximum plasma concentration, given sampling scheme</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Drug Concentration (Tmax) and Half-life</measure>
    <time_frame>Day 5 (7 time points)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Drug Concentration/Minimum Inhibitory Concentration (Cmax/MIC)</measure>
    <time_frame>Day 5 (7 time points)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Area Under the Curve (AUC) During First 12 and 24 Hours</measure>
    <time_frame>Day 5 (7 time points)</time_frame>
    <description>Area under the curve (AUC), from time 0-12 hours for INH or 0-24 hours for gatifloxacin, levofloxacin, and moxifloxacin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve During First 12 or 24 Hours / Minimum Inhibitory Concentration (AUC/MIC)</measure>
    <time_frame>Day 5 (7 time points)</time_frame>
    <description>Area Under the Curve (AUC) During First 12 or 24 Hours /Minimum Inhibitory Concentration. AUC reflects total drug (bound and unbound). MIC values were determined using protein-containing media.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Drug Concentration (Cmax)</measure>
    <time_frame>Day 5 (7 time points)</time_frame>
    <description>Maximum Plasma Drug Concentration (Cmax), given sampling scheme</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Area Under the Curve During First 12 and 24 Hours</measure>
    <time_frame>Day 5 (7 time points)</time_frame>
    <description>Median pharmacokinetic parameters (range). AUC 0-12 and AUC 0-24 = area under the curve during the first 12 and 24 hours after dosing, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Drug Concentrations (Cmax), Adjusted for Free Drug Concentration</measure>
    <time_frame>Day 5 (7 time points)</time_frame>
    <description>Cmax adjusted for free drug concentrations after 5 days of monotherapy with study drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Drug Concentration/Minimum Inhibitory Concentration (Cmax/MIC) Adjusted for Free Drug Concentrations</measure>
    <time_frame>Day 5 (7 time points)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) During First 12 and 24 Hours Adjusted for Free Drug Concentrations</measure>
    <time_frame>Day 5 (7 time points)</time_frame>
    <description>Median pharmacodynamic parameters (range) adjusted for free drug concentrations. AUC 0-12 and AUC 0-24 = area under the curve during the first 12 and 24 hours after dosing, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) Adjusted for Free Drug Concentrations/Minimum Inhibitory Concentration (MIC)</measure>
    <time_frame>Day 5 (7 time points)</time_frame>
    <description>Area Under the Curve 0-12 (AUC 0-12) Adjusted for Free Drug Concentrations/Minimum Inhibitory Concentration (MIC) and AUC 0-24/MIC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Dosing Interval Above Minimum Inhibitory Concentration (MIC)</measure>
    <time_frame>Day 5 (7 time points)</time_frame>
    <description>Determined by linear extrapolation of concentration-versus-time curve to intersection with MIC.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>TB Multi-drug Resistant</condition>
  <arm_group>
    <arm_group_label>Linezolid once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects to receive linezolid 600 mg orally once daily for 7days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levofloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects to receive levofloxacin 1000 mg orally once daily for 7days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects to receive moxifloxacin 400 mg orally once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linezolid every 12 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects to receive linezolid 600 mg orally every 12 hours daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isoniazid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 subjects to receive isoniazid 300 mg orally once daily for 7days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gatifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects to receive gatifloxacin 400 mg orally once daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gatifloxacin</intervention_name>
    <description>Gatifloxacin 400 mg/day x 7 days.</description>
    <arm_group_label>Gatifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>Levofloxacin 1000 mg/day x 7 days.</description>
    <arm_group_label>Levofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin 400 mg/day x 7 days.</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>Isoniazid 300 mg/day x 7 days.</description>
    <arm_group_label>Isoniazid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.</description>
    <arm_group_label>Linezolid every 12 hours</arm_group_label>
    <arm_group_label>Linezolid once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults, male or female, age 18 to 65 years.

          -  Women with child-bearing potential (not surgically sterilized or postmenopausal for
             less than 1 year) must be using or agree to use an adequate method of birth control
             [condom; intravaginal spermicide (foams, jellies, sponge) and diaphragm; cervical cap
             or intrauterine device] during study drug treatment.

          -  Newly diagnosed sputum smear-positive pulmonary tuberculosis as confirmed by sputum
             acid fast bacilli (AFB) smear and chest X-ray findings consistent with pulmonary
             tuberculosis.

          -  Willing and able to provide informed consent.

          -  Reasonably normal hemoglobin (greater than or equal to 8 gm/dL), renal function (serum
             creatinine less than 2 mg/dL), hepatic function [serum aspartate aminotransferase
             (AST) less than 1.5 times the upper limit of normal for the testing laboratory and
             total bilirubin less than 1.3 mg/dL], and random blood glucose less than 150 mg/dL.

        Exclusion Criteria:

          -  Human immunodeficiency virus (HIV) infection.

          -  Weight less than 75 percent of ideal body weight.

          -  Presence of significant hemoptysis. Patients who cough up frank blood (more than blood
             streaked sputum) will not be eligible for enrollment.

          -  Pregnant or breastfeeding women and those who are not practicing birth control.

          -  Significant respiratory impairment (respiratory rate greater than 35/minute).

          -  Clinical suspicion of disseminated tuberculosis or tuberculosis meningitis.

          -  Presence of serious underlying medical illness, such as liver failure, renal failure,
             diabetes mellitus, chronic alcoholism, decompensated heart failure, hematologic
             malignancy or patients receiving myelosuppressive chemotherapy.

          -  Patients receiving any of the following medications - monoamine oxidase inhibitors
             (phenelzine, tranylcypromine), adrenergic/serotonergic agonists such as
             pseudoephedrine and phenylpropanolamine (frequently found in cold and cough remedies),
             tricyclic antidepressants (amitriptyline, nortriptyline, protriptyline, doxepin,
             amoxapine, etc), antipsychotics such as chlorpromazine and buspirone, serotonin
             re-uptake inhibitors (fluoxetine, paroxetine, sertraline, etc.), buproprion, agents
             known to prolong the QTc interval [erythromycin, clarithromycin, astemizole, type Ia
             (quinidine, procainamide, disopyramide) and III (amiodarone, sotalol)
             anti-arrhythmics, carbamazepine, insulin, sulfonylureas, and meperidine.

          -  Presence of QTc prolongation (greater than 450 msec) on baseline electrocardiogram
             (EKG).

          -  Allergy or contraindication to use of study drugs.

          -  Treatment with antituberculosis medications or other antibiotics with known activity
             against M. tuberculosis during the preceding 6 months.

          -  Inability to provide informed consent.

          -  Total white blood cell count less than 3000/mm^3.

          -  Platelet count less than 150,000/mm^3.

          -  Patients with suspected drug resistant tuberculosis (e.g., contact to source patient
             with drug resistant tuberculosis, patients who have relapsed after previous treatment
             for tuberculosis).

          -  Patients likely, in the opinion of the local investigator, to be unable to comply with
             the requirements of the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal do Espirito Santo/HUCAM</name>
      <address>
        <city>Vitoria</city>
        <zip>29040-091</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2006 Jun;10(6):605-12.</citation>
    <PMID>16776446</PMID>
  </results_reference>
  <results_reference>
    <citation>McGee B, Dietze R, Hadad DJ, Molino LP, Maciel EL, Boom WH, Palaci M, Johnson JL, Peloquin CA. Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2009 Sep;53(9):3981-4. doi: 10.1128/AAC.01378-08. Epub 2009 Jun 29.</citation>
    <PMID>19564361</PMID>
  </results_reference>
  <results_reference>
    <citation>Li L, Mahan CS, Palaci M, Horter L, Loeffelholz L, Johnson JL, Dietze R, Debanne SM, Joloba ML, Okwera A, Boom WH, Eisenach KD. Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy. J Clin Microbiol. 2010 Jan;48(1):46-51. doi: 10.1128/JCM.01526-09. Epub 2009 Nov 18.</citation>
    <PMID>19923475</PMID>
  </results_reference>
  <results_reference>
    <citation>Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008 Mar;52(3):852-7. Epub 2007 Dec 10.</citation>
    <PMID>18070980</PMID>
  </results_reference>
  <results_reference>
    <citation>Dietze R, Hadad DJ, McGee B, Molino LP, Maciel EL, Peloquin CA, Johnson DF, Debanne SM, Eisenach K, Boom WH, Palaci M, Johnson JL. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med. 2008 Dec 1;178(11):1180-5. doi: 10.1164/rccm.200806-892OC. Epub 2008 Sep 11.</citation>
    <PMID>18787216</PMID>
  </results_reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2006</study_first_submitted>
  <study_first_submitted_qc>November 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2006</study_first_posted>
  <results_first_submitted>November 19, 2008</results_first_submitted>
  <results_first_submitted_qc>May 7, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 25, 2009</results_first_posted>
  <last_update_submitted>June 9, 2011</last_update_submitted>
  <last_update_submitted_qc>June 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, ORA</name_title>
    <organization>HHS/NIAID/DMID</organization>
  </responsible_party>
  <keyword>tuberculosis, linezolid, gatifloxacin, levofloxacin, isoniazid, moxifloxacin, Brazil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Gatifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Screening for the trial began in February 2004 in Vitória, Brazil. Non-HIV infected adults aged 18-65 years with suspected pulmonary tuberculosis (TB) were recruited at local TB posts and the Hospital Universitario Cassiano Antonio de Moraes of the Universidade Federal do Espírito Santo (UFES) in Vitória. Enrollment was completed in October 2007.</recruitment_details>
      <pre_assignment_details>A total of 113 adults with suspected pulmonary TB were evaluated for study participation. Forty-three were excluded because they did not meet the eligibility criteria, leaving a total of 70 patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gatifloxacin 400 mg/Day</title>
          <description>Gatifloxacin 400 mg/day x 7 days</description>
        </group>
        <group group_id="P2">
          <title>Levofloxacin 1000 mg/Day</title>
          <description>Levofloxacin 1000 mg/day x 7days</description>
        </group>
        <group group_id="P3">
          <title>Linezolid 600 mg / Once Daily</title>
          <description>Linezolid 600 mg/once daily x 7days</description>
        </group>
        <group group_id="P4">
          <title>Linezolid 600 mg / Twice Daily</title>
          <description>Linezolid 600 mg twice daily x 7 days</description>
        </group>
        <group group_id="P5">
          <title>Moxifloxacin 400 mg/Day</title>
          <description>Moxifloxacin 400 mg/day x 7 days</description>
        </group>
        <group group_id="P6">
          <title>Isoniazid (INH) 300 mg/Day</title>
          <description>Isoniazid (INH) 300 mg/day x 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gatifloxacin 400 mg/Day</title>
          <description>Gatifloxacin 400 mg/day x 7 days</description>
        </group>
        <group group_id="B2">
          <title>Levofloxacin 1000 mg/Day</title>
          <description>Levofloxacin 1000 mg/day x 7days</description>
        </group>
        <group group_id="B3">
          <title>Linezolid 600 mg / Once Daily</title>
          <description>Linezolid 600 mg/once daily x 7days</description>
        </group>
        <group group_id="B4">
          <title>Linezolid 600 mg / Twice Daily</title>
          <description>Linezolid 600 mg twice daily x 7 days</description>
        </group>
        <group group_id="B5">
          <title>Moxifloxacin 400 mg/Day</title>
          <description>Moxifloxacin 400 mg/day x 7 days</description>
        </group>
        <group group_id="B6">
          <title>Isoniazid (INH) 300 mg/Day</title>
          <description>Isoniazid (INH) 300 mg/day x 7 days</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="20"/>
            <count group_id="B7" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="10.1" lower_limit="27.0" upper_limit="40.0"/>
                    <measurement group_id="B2" value="43.5" spread="6.4" lower_limit="42.0" upper_limit="46.0"/>
                    <measurement group_id="B3" value="33.5" spread="13.4" lower_limit="23.0" upper_limit="42.0"/>
                    <measurement group_id="B4" value="45.0" spread="12.7" lower_limit="39.0" upper_limit="48.0"/>
                    <measurement group_id="B5" value="35.0" spread="8.4" lower_limit="25.0" upper_limit="37.0"/>
                    <measurement group_id="B6" value="33.0" spread="11.4" lower_limit="23.0" upper_limit="43.5"/>
                    <measurement group_id="B7" value="35.0" spread="11.2" lower_limit="26.0" upper_limit="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC)</title>
        <description>The adjusted area under the curve (aAUC) for sputum colony forming units (cfu) for each day on treatment was calculated. The aAUC represents the percentage of the expected AUC given no change in log cfu in response to study drug administration.</description>
        <time_frame>Study drug administration duration - 7 days monotherapy</time_frame>
        <population>The aAUC was calculated for 10 subjects per treatment arm (n=40).</population>
        <group_list>
          <group group_id="O1">
            <title>Gatifloxacin 400 mg/Day</title>
            <description>Gatifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin 1000 mg/Day</title>
            <description>Levofloxacin 1000 mg/day x 7days</description>
          </group>
          <group group_id="O3">
            <title>Moxifloxacin 400 mg/Day</title>
            <description>Moxifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O4">
            <title>Isoniazid (INH) 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC)</title>
          <description>The adjusted area under the curve (aAUC) for sputum colony forming units (cfu) for each day on treatment was calculated. The aAUC represents the percentage of the expected AUC given no change in log cfu in response to study drug administration.</description>
          <population>The aAUC was calculated for 10 subjects per treatment arm (n=40).</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.03"/>
                    <measurement group_id="O2" value="0.98" spread="0.03"/>
                    <measurement group_id="O3" value="0.96" spread="0.04"/>
                    <measurement group_id="O4" value="0.95" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="0.03"/>
                    <measurement group_id="O2" value="0.95" spread="0.05"/>
                    <measurement group_id="O3" value="0.94" spread="0.06"/>
                    <measurement group_id="O4" value="0.90" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.05"/>
                    <measurement group_id="O2" value="0.91" spread="0.07"/>
                    <measurement group_id="O3" value="0.91" spread="0.08"/>
                    <measurement group_id="O4" value="0.87" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.07"/>
                    <measurement group_id="O2" value="0.88" spread="0.08"/>
                    <measurement group_id="O3" value="0.89" spread="0.09"/>
                    <measurement group_id="O4" value="0.84" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="0.08"/>
                    <measurement group_id="O2" value="0.85" spread="0.09"/>
                    <measurement group_id="O3" value="0.87" spread="0.10"/>
                    <measurement group_id="O4" value="0.81" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.08"/>
                    <measurement group_id="O2" value="0.83" spread="0.10"/>
                    <measurement group_id="O3" value="0.85" spread="0.10"/>
                    <measurement group_id="O4" value="0.80" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.09"/>
                    <measurement group_id="O2" value="0.81" spread="0.10"/>
                    <measurement group_id="O3" value="0.83" spread="0.10"/>
                    <measurement group_id="O4" value="0.80" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mean adjusted aAUC for all 4 treatment groups over the 7 days of study drug administration</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1. Pooled sputum bacillary load data for patients in the 3 fluoroquinolones arms were combined and compared to that of patients in the INH arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 2. Pooled sputum bacillary load data for patients in the 3 fluoroquinolones arms were combined and compared to that of patients in the INH arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 3. Pooled sputum bacillary load data for patients in the 3 fluoroquinolones arms were combined and compared to that of patients in the INH arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 4. Pooled sputum bacillary load data for patients in the 3 fluoroquinolones arms were combined and compared to that of patients in the INH arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 5. Pooled sputum bacillary load data for patients in the 3 fluoroquinolones arms were combined and compared to that of patients in the INH arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 6. Pooled sputum bacillary load data for patients in the 3 fluoroquinolones arms were combined and compared to that of patients in the INH arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.091</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 7. Pooled sputum bacillary load data for patients in the 3 fluoroquinolones arms were combined and compared to that of patients in the INH arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.354</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum mRNA Clearance Rate - Results Are Pending.</title>
        <time_frame>Study drug administration duration</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Cytokine Proteins - Results Are Pending.</title>
        <time_frame>Study drug administration duration</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Drug Concentration (Cmax)</title>
        <description>Maximum plasma concentration, given sampling scheme</description>
        <time_frame>Day 5 (7 time points)</time_frame>
        <population>Thirty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. Plasma samples were collected at 7 time points on the 5th day after beginning study drug monotherapy. One subject in the moxifloxacin arm was discontinued from the study before day 5 and did not undergo PK sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Gatifloxacin 400 mg/Day</title>
            <description>Gatifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin 1000 mg/Day</title>
            <description>Levofloxacin 1000 mg/day x 7days</description>
          </group>
          <group group_id="O3">
            <title>Moxifloxacin 400 mg/Day</title>
            <description>Moxifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O4">
            <title>Isoniazid (INH) 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Drug Concentration (Cmax)</title>
          <description>Maximum plasma concentration, given sampling scheme</description>
          <population>Thirty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. Plasma samples were collected at 7 time points on the 5th day after beginning study drug monotherapy. One subject in the moxifloxacin arm was discontinued from the study before day 5 and did not undergo PK sampling.</population>
          <units>ug/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="3.8" upper_limit="6.4"/>
                    <measurement group_id="O2" value="15.6" lower_limit="8.6" upper_limit="43.0"/>
                    <measurement group_id="O3" value="6.1" lower_limit="4.5" upper_limit="9.0"/>
                    <measurement group_id="O4" value="3.6" lower_limit="2.5" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference in Sputum Bacillary Loads: Early Bactericidal Activity (EBA) Days 0 to 2; Fluoroquinolones/Isoniazid (INH) Comparison</title>
        <description>Early bactericidal activity (EBA 0-2) was calculated as the rate of fall in sputum colony forming units (cfu) (expressed in log10 units) during the first 2 days of monotherapy.</description>
        <time_frame>Day 0 to Day 2 Monotherapy</time_frame>
        <population>Early bactericidal activity (EBA 0-2) was calculated for 10 subjects per treatment arm (n=40).</population>
        <group_list>
          <group group_id="O1">
            <title>Gatifloxacin 400 mg/Day</title>
            <description>Gatifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin 1000 mg/Day</title>
            <description>Levofloxacin 1000 mg/day x 7days</description>
          </group>
          <group group_id="O3">
            <title>Moxifloxacin 400 mg/Day</title>
            <description>Moxifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O4">
            <title>Isoniazid (INH) 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Sputum Bacillary Loads: Early Bactericidal Activity (EBA) Days 0 to 2; Fluoroquinolones/Isoniazid (INH) Comparison</title>
          <description>Early bactericidal activity (EBA 0-2) was calculated as the rate of fall in sputum colony forming units (cfu) (expressed in log10 units) during the first 2 days of monotherapy.</description>
          <population>Early bactericidal activity (EBA 0-2) was calculated for 10 subjects per treatment arm (n=40).</population>
          <units>log10 cfu/ml/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.27"/>
                    <measurement group_id="O2" value="0.45" spread="0.35"/>
                    <measurement group_id="O3" value="0.33" spread="0.39"/>
                    <measurement group_id="O4" value="0.67" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mean values of EBA Days 0 to 2 for the 4 treatment groups were compared.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Two way comparison of INH against gatifloxacin using a simultaneous non-parametric procedure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Two way comparison of INH against moxifloxacin using a simultaneous non-parametric procedure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Two way comparison of INH against levofloxacin using a simultaneous non-parametric procedure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Extended Early Bactericidal Activity (EBA) From Days 2 to 7; Fluoroquinolones/Isoniazid (INH) Comparison</title>
        <description>The rate of fall in sputum cfu between day 2 and day 7 of monotherapy was estimated by the slope of the linear regression obtained by fitting the 6 sputum cfu values corresponding to Days 2 through 7.</description>
        <time_frame>Day 2 to Day 7 Monotherapy</time_frame>
        <population>A total of 38 patients were analyzed for Early Bactericidal Activity (EBA) Days 2-7. One patient in the moxifloxacin arm discontinued the study drug after 4 days. One patient in the INH arm discontinued the study drug after 6 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Gatifloxacin 400 mg/Day</title>
            <description>Gatifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin 1000 mg/Day</title>
            <description>Levofloxacin 1000 mg/day x 7days</description>
          </group>
          <group group_id="O3">
            <title>Moxifloxacin 400 mg/Day</title>
            <description>Moxifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O4">
            <title>Isoniazid (INH) 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Extended Early Bactericidal Activity (EBA) From Days 2 to 7; Fluoroquinolones/Isoniazid (INH) Comparison</title>
          <description>The rate of fall in sputum cfu between day 2 and day 7 of monotherapy was estimated by the slope of the linear regression obtained by fitting the 6 sputum cfu values corresponding to Days 2 through 7.</description>
          <population>A total of 38 patients were analyzed for Early Bactericidal Activity (EBA) Days 2-7. One patient in the moxifloxacin arm discontinued the study drug after 4 days. One patient in the INH arm discontinued the study drug after 6 days.</population>
          <units>log10 cfu/ml/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.13"/>
                    <measurement group_id="O2" value="0.18" spread="0.13"/>
                    <measurement group_id="O3" value="0.17" spread="0.09"/>
                    <measurement group_id="O4" value="0.08" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mean values of EBA Days 2 to 7 for the 4 treatment groups were compared.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The rate of fall in sputum cfu for the 4 treatment groups between day 2 and day 7 of monotherapy was estimated by the slope of the linear regression obtained from fitting the 6 sputum cfu values corresponding to days 2 through 7.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>EBA Days 2-7 for patients in the 3 fluoroquinolone groups were pooled and compared to bactericidal activity of patients in the INH arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC)</title>
        <description>The adjusted area under the curve (aAUC) for sputum colony forming unit (cfu) for each day on treatment was calculated for patients in the INH arm and those in the Linezolid once daily and Linezolid twice daily arms. The aAUC represents the percentage of the expected AUC given no change in log cfu in response to study drug administration.</description>
        <time_frame>Study drug administration duration - 7 days monotherapy</time_frame>
        <population>The aAUC was calculated for 29 patients. One patient in the linezolid twice daily arm withdrew after randomization before receiving any doses of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Isoniazid 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Linezolid 600 mg/Once Daily</title>
            <description>Linezolid, 600 mg/day x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Linezolid 600 mg/Twice Daily</title>
            <description>Linezolid 600 mg q12h x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC)</title>
          <description>The adjusted area under the curve (aAUC) for sputum colony forming unit (cfu) for each day on treatment was calculated for patients in the INH arm and those in the Linezolid once daily and Linezolid twice daily arms. The aAUC represents the percentage of the expected AUC given no change in log cfu in response to study drug administration.</description>
          <population>The aAUC was calculated for 29 patients. One patient in the linezolid twice daily arm withdrew after randomization before receiving any doses of study drug.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.06"/>
                    <measurement group_id="O2" value="0.98" spread="0.04"/>
                    <measurement group_id="O3" value="0.98" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.08"/>
                    <measurement group_id="O2" value="0.97" spread="0.07"/>
                    <measurement group_id="O3" value="0.96" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.03"/>
                    <measurement group_id="O2" value="0.96" spread="0.07"/>
                    <measurement group_id="O3" value="0.95" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.09"/>
                    <measurement group_id="O2" value="0.96" spread="0.07"/>
                    <measurement group_id="O3" value="0.94" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.10"/>
                    <measurement group_id="O2" value="0.95" spread="0.07"/>
                    <measurement group_id="O3" value="0.94" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.12"/>
                    <measurement group_id="O2" value="0.95" spread="0.07"/>
                    <measurement group_id="O3" value="0.93" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.07"/>
                    <measurement group_id="O2" value="0.95" spread="0.07"/>
                    <measurement group_id="O3" value="0.93" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mean adjusted aAUC for all 3 treatment groups over the 7 days of study drug administration</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1. Pooled sputum bacillary load data for patients in the linezolid arms were combined and compared to that of patients in the INH arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2. Pooled sputum bacillary load data for patients in the linezolid arms were combined and compared to that of patients in the INH arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3. Pooled sputum bacillary load data for patients in the linezolid arms were combined and compared to that of patients in the INH arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4. Pooled sputum bacillary load data for patients in the linezolid arms were combined and compared to that of patients in the INH arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5. Pooled sputum bacillary load data for patients in the linezolid arms were combined and compared to that of patients in the INH arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 6. Pooled sputum bacillary load data for patients in the linezolid arms were combined and compared to that of patients in the INH arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 7. Pooled sputum bacillary load data for patients in the linezolid arms were combined and compared to that of patients in the INH arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference in Sputum Bacillary Loads: Early Bactericidal Activity (EBA) Days 0 to 2; Linezolid Once Daily/Linezolid Twice Daily/Isoniazid (INH) Comparison</title>
        <description>Early bactericidal activity (EBA 0-2) was calculated as the rate of fall in sputum cfu (expressed in log10 units) during the first 2 days of monotherapy. Mean values for the 3 treatment groups were compared.</description>
        <time_frame>Day 0 to Day 2 Monotherapy</time_frame>
        <population>EBA 0-2 comparisons across groups were done for 29 patients. One patient in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Isoniazid 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Linezolid 600 mg/Once Daily</title>
            <description>Linezolid, 600 mg/day x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Linezolid 600 mg/Twice Daily</title>
            <description>Linezolid 600 mg q12h x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Sputum Bacillary Loads: Early Bactericidal Activity (EBA) Days 0 to 2; Linezolid Once Daily/Linezolid Twice Daily/Isoniazid (INH) Comparison</title>
          <description>Early bactericidal activity (EBA 0-2) was calculated as the rate of fall in sputum cfu (expressed in log10 units) during the first 2 days of monotherapy. Mean values for the 3 treatment groups were compared.</description>
          <population>EBA 0-2 comparisons across groups were done for 29 patients. One patient in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
          <units>log10 cfu/ml/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.35"/>
                    <measurement group_id="O2" value="0.18" spread="0.27"/>
                    <measurement group_id="O3" value="0.26" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mean values of EBA Days 0 to 2 for the 3 treatments groups were compared.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Two way comparison of INH against Linezolid once daily using a simultaneous non-parametric procedure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mean EBA 0-2 of INH was compared to pooled Linezolid once daily and Linezolid twice daily results.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Drug Concentration (Tmax) and Half-life</title>
        <time_frame>Day 5 (7 time points)</time_frame>
        <population>Thirty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. One subject in the moxifloxacin arm was discontinued from the study before day 5 and did not undergo PK sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Gatifloxacin 400 mg/Day</title>
            <description>Gatifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin 1000 mg/Day</title>
            <description>Levofloxacin 1000 mg/day x 7days</description>
          </group>
          <group group_id="O3">
            <title>Moxifloxacin 400 mg/Day</title>
            <description>Moxifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O4">
            <title>Isoniazid (INH) 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Drug Concentration (Tmax) and Half-life</title>
          <population>Thirty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. One subject in the moxifloxacin arm was discontinued from the study before day 5 and did not undergo PK sampling.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O4" value="1" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Half-life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="5.2" upper_limit="9.3"/>
                    <measurement group_id="O2" value="7.6" lower_limit="4.4" upper_limit="19.1"/>
                    <measurement group_id="O3" value="8.1" lower_limit="5.1" upper_limit="9.9"/>
                    <measurement group_id="O4" value="2.5" lower_limit="1.5" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Drug Concentration/Minimum Inhibitory Concentration (Cmax/MIC)</title>
        <time_frame>Day 5 (7 time points)</time_frame>
        <population>Thirty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. One subject in the moxifloxacin arm was discontinued from the study before day 5 and did not undergo PK sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Gatifloxacin 400 mg/Day</title>
            <description>Gatifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin 1000 mg/Day</title>
            <description>Levofloxacin 1000 mg/day x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Moxifloxacin 400 mg/Day</title>
            <description>Moxifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O4">
            <title>Isoniazid (INH) 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Drug Concentration/Minimum Inhibitory Concentration (Cmax/MIC)</title>
          <population>Thirty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. One subject in the moxifloxacin arm was discontinued from the study before day 5 and did not undergo PK sampling.</population>
          <units>ug/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="8.4" upper_limit="11.3"/>
                    <measurement group_id="O2" value="15.6" lower_limit="12.2" upper_limit="16.6"/>
                    <measurement group_id="O3" value="12.3" lower_limit="9.6" upper_limit="13.4"/>
                    <measurement group_id="O4" value="70.6" lower_limit="64.0" upper_limit="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference in Sputum Bacillary Loads: Extended Early Bactericidal Activity (EBA) From Days 2 to 7; Linezolid Once Daily/Linezolid Twice Daily/INH Comparison</title>
        <description>The rate of fall in sputum cfu between day 2 and day 7 of monotherapy was estimated by the slope of the linear regression obtained by fitting the 6 sputum cfu values corresponding to Days 2 through 7.</description>
        <time_frame>Day 2 to Day 7 Monotherapy</time_frame>
        <population>One patient in the INH arm discontinued the study drug after 5 days. Days 3 and 7 cultures for another patient in the INH arm were contaminated and cfu data are not available for this patient. One patient in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Isoniazid 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Linezolid 600 mg/Once Daily</title>
            <description>Linezolid, 600 mg/day x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Linezolid 600 mg/Twice Daily</title>
            <description>Linezolid 600 mg q12h x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Sputum Bacillary Loads: Extended Early Bactericidal Activity (EBA) From Days 2 to 7; Linezolid Once Daily/Linezolid Twice Daily/INH Comparison</title>
          <description>The rate of fall in sputum cfu between day 2 and day 7 of monotherapy was estimated by the slope of the linear regression obtained by fitting the 6 sputum cfu values corresponding to Days 2 through 7.</description>
          <population>One patient in the INH arm discontinued the study drug after 5 days. Days 3 and 7 cultures for another patient in the INH arm were contaminated and cfu data are not available for this patient. One patient in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
          <units>log10 cfu/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.11"/>
                    <measurement group_id="O2" value="0.09" spread="0.17"/>
                    <measurement group_id="O3" value="0.04" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mean values EBA Days 2-7 for the 3 treatment groups were compared.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The rate of fall in sputum cfu for the 3 treatment groups between day 2 and day 7 of monotherapy was estimated by the slope of the linear regression obtained from fitting the 6 sputum cfu values corresponding to days 2 through 7.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>EBA Days 2-7 for INH was compared to that of the pooled linezolid arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters: Area Under the Curve (AUC) During First 12 and 24 Hours</title>
        <description>Area under the curve (AUC), from time 0-12 hours for INH or 0-24 hours for gatifloxacin, levofloxacin, and moxifloxacin.</description>
        <time_frame>Day 5 (7 time points)</time_frame>
        <population>Thirty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. Plasma samples were collected at 7 time points on the 5th day after beginning study drug monotherapy. One subject in the moxifloxacin arm was discontinued from the study before day 5 and did not undergo PK sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Gatifloxacin 400 mg/Day</title>
            <description>Gatifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin 1000 mg/Day</title>
            <description>Levofloxacin 1000 mg/day x 7days</description>
          </group>
          <group group_id="O3">
            <title>Moxifloxacin 400 mg/Day</title>
            <description>Moxifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O4">
            <title>Isoniazid (INH) 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters: Area Under the Curve (AUC) During First 12 and 24 Hours</title>
          <description>Area under the curve (AUC), from time 0-12 hours for INH or 0-24 hours for gatifloxacin, levofloxacin, and moxifloxacin.</description>
          <population>Thirty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. Plasma samples were collected at 7 time points on the 5th day after beginning study drug monotherapy. One subject in the moxifloxacin arm was discontinued from the study before day 5 and did not undergo PK sampling.</population>
          <units>ug/h/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8" lower_limit="31.7" upper_limit="51.0"/>
                    <measurement group_id="O2" value="129.1" lower_limit="103.4" upper_limit="358.3"/>
                    <measurement group_id="O3" value="55.3" lower_limit="36.0" upper_limit="79.1"/>
                    <measurement group_id="O4" value="11.9" lower_limit="7.1" upper_limit="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve During First 12 or 24 Hours / Minimum Inhibitory Concentration (AUC/MIC)</title>
        <description>Area Under the Curve (AUC) During First 12 or 24 Hours /Minimum Inhibitory Concentration. AUC reflects total drug (bound and unbound). MIC values were determined using protein-containing media.</description>
        <time_frame>Day 5 (7 time points)</time_frame>
        <population>Thirty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. One subject in the moxifloxacin arm was discontinued from the study before day 5 and did not undergo PK sampling</population>
        <group_list>
          <group group_id="O1">
            <title>Gatifloxacin 400 mg/Day</title>
            <description>Gatifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin 1000 mg/Day</title>
            <description>Levofloxacin 1000 mg/day x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Moxifloxacin 400 mg/Day</title>
            <description>Moxifloxacin 400 mg/day x 7 days</description>
          </group>
          <group group_id="O4">
            <title>Isoniazid (INH) 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve During First 12 or 24 Hours / Minimum Inhibitory Concentration (AUC/MIC)</title>
          <description>Area Under the Curve (AUC) During First 12 or 24 Hours /Minimum Inhibitory Concentration. AUC reflects total drug (bound and unbound). MIC values were determined using protein-containing media.</description>
          <population>Thirty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. One subject in the moxifloxacin arm was discontinued from the study before day 5 and did not undergo PK sampling</population>
          <units>ug/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.6" lower_limit="70.7" upper_limit="89.7"/>
                    <measurement group_id="O2" value="129.1" lower_limit="121.0" upper_limit="145.0"/>
                    <measurement group_id="O3" value="110.5" lower_limit="98.9" upper_limit="121.6"/>
                    <measurement group_id="O4" value="215.2" lower_limit="177.4" upper_limit="329.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Drug Concentration (Cmax)</title>
        <description>Maximum Plasma Drug Concentration (Cmax), given sampling scheme</description>
        <time_frame>Day 5 (7 time points)</time_frame>
        <population>Twenty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Isoniazid 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Linezolid 600 mg/Once Daily</title>
            <description>Linezolid, 600 mg/day x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Linezolid 600 mg/Twice Daily</title>
            <description>Linezolid 600 mg q12h x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Drug Concentration (Cmax)</title>
          <description>Maximum Plasma Drug Concentration (Cmax), given sampling scheme</description>
          <population>Twenty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
          <units>ug/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.5" upper_limit="5.3"/>
                    <measurement group_id="O2" value="15.0" lower_limit="11.9" upper_limit="21.3"/>
                    <measurement group_id="O3" value="19.4" lower_limit="11.8" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Drug Concentration (Tmax) and Half-life</title>
        <time_frame>Day 5 (7 time points)</time_frame>
        <population>Twenty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Isoniazid 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Linezolid 600 mg/Once Daily</title>
            <description>Linezolid, 600 mg/day x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Linezolid 600 mg/Twice Daily</title>
            <description>Linezolid 600 mg q12h x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Drug Concentration (Tmax) and Half-life</title>
          <population>Twenty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax in h (apparent time of max plasma conc.)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Half-life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="1.1" upper_limit="4.5"/>
                    <measurement group_id="O2" value="3.20" lower_limit="1.5" upper_limit="5.0"/>
                    <measurement group_id="O3" value="4.56" lower_limit="2.1" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters: Area Under the Curve During First 12 and 24 Hours</title>
        <description>Median pharmacokinetic parameters (range). AUC 0-12 and AUC 0-24 = area under the curve during the first 12 and 24 hours after dosing, respectively</description>
        <time_frame>Day 5 (7 time points)</time_frame>
        <population>Twenty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Isoniazid 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Linezolid 600 mg/Once Daily</title>
            <description>Linezolid, 600 mg/day x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Linezolid 600 mg/Twice Daily</title>
            <description>Linezolid 600 mg q12h x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters: Area Under the Curve During First 12 and 24 Hours</title>
          <description>Median pharmacokinetic parameters (range). AUC 0-12 and AUC 0-24 = area under the curve during the first 12 and 24 hours after dosing, respectively</description>
          <population>Twenty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
          <units>ug/h/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-12 (ug/h/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="6.5" upper_limit="26.9"/>
                    <measurement group_id="O2" value="87.0" lower_limit="47.5" upper_limit="119.3"/>
                    <measurement group_id="O3" value="116.4" lower_limit="50.4" upper_limit="197.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-24 (ug/h/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" lower_limit="6.5" upper_limit="29.0"/>
                    <measurement group_id="O2" value="96.9" lower_limit="47.8" upper_limit="143.7"/>
                    <measurement group_id="O3" value="232.9" lower_limit="100.8" upper_limit="394.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Drug Concentrations (Cmax), Adjusted for Free Drug Concentration</title>
        <description>Cmax adjusted for free drug concentrations after 5 days of monotherapy with study drugs</description>
        <time_frame>Day 5 (7 time points)</time_frame>
        <population>Twenty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Isoniazid 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Linezolid 600 mg/Once Daily</title>
            <description>Linezolid, 600 mg/day x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Linezolid 600 mg/Twice Daily</title>
            <description>Linezolid 600 mg q12h x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Drug Concentrations (Cmax), Adjusted for Free Drug Concentration</title>
          <description>Cmax adjusted for free drug concentrations after 5 days of monotherapy with study drugs</description>
          <population>Twenty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
          <units>ug/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="2.5" upper_limit="4.8"/>
                    <measurement group_id="O2" value="10.3" lower_limit="8.2" upper_limit="14.7"/>
                    <measurement group_id="O3" value="13.4" lower_limit="8.1" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Drug Concentration/Minimum Inhibitory Concentration (Cmax/MIC) Adjusted for Free Drug Concentrations</title>
        <time_frame>Day 5 (7 time points)</time_frame>
        <population>Twenty-nine patients underwent pharmacodynamic sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Isoniazid 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Linezolid 600 mg/Once Daily</title>
            <description>Linezolid, 600 mg/day x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Linezolid 600 mg/Twice Daily</title>
            <description>Linezolid 600 mg q12h x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Drug Concentration/Minimum Inhibitory Concentration (Cmax/MIC) Adjusted for Free Drug Concentrations</title>
          <population>Twenty-nine patients underwent pharmacodynamic sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
          <units>ug/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" lower_limit="51.0" upper_limit="77.3"/>
                    <measurement group_id="O2" value="20.0" lower_limit="10.2" upper_limit="21.9"/>
                    <measurement group_id="O3" value="16.2" lower_limit="14.3" upper_limit="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) During First 12 and 24 Hours Adjusted for Free Drug Concentrations</title>
        <description>Median pharmacodynamic parameters (range) adjusted for free drug concentrations. AUC 0-12 and AUC 0-24 = area under the curve during the first 12 and 24 hours after dosing, respectively</description>
        <time_frame>Day 5 (7 time points)</time_frame>
        <population>Twenty-nine patients underwent pharmacodynamic (PD) sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Isoniazid 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Linezolid 600 mg/Once Daily</title>
            <description>Linezolid, 600 mg/day x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Linezolid 600 mg/Twice Daily</title>
            <description>Linezolid 600 mg q12h x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) During First 12 and 24 Hours Adjusted for Free Drug Concentrations</title>
          <description>Median pharmacodynamic parameters (range) adjusted for free drug concentrations. AUC 0-12 and AUC 0-24 = area under the curve during the first 12 and 24 hours after dosing, respectively</description>
          <population>Twenty-nine patients underwent pharmacodynamic (PD) sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
          <units>ug/h/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" lower_limit="5.8" upper_limit="24.2"/>
                    <measurement group_id="O2" value="60.1" lower_limit="32.8" upper_limit="82.3"/>
                    <measurement group_id="O3" value="80.3" lower_limit="34.8" upper_limit="136.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" lower_limit="5.8" upper_limit="26.1"/>
                    <measurement group_id="O2" value="66.8" lower_limit="33.0" upper_limit="99.2"/>
                    <measurement group_id="O3" value="160.7" lower_limit="134.4" upper_limit="225.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) Adjusted for Free Drug Concentrations/Minimum Inhibitory Concentration (MIC)</title>
        <description>Area Under the Curve 0-12 (AUC 0-12) Adjusted for Free Drug Concentrations/Minimum Inhibitory Concentration (MIC) and AUC 0-24/MIC</description>
        <time_frame>Day 5 (7 time points)</time_frame>
        <population>Twenty-nine patients underwent pharmacodynamic (PD) sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Isoniazid 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Linezolid 600 mg/Once Daily</title>
            <description>Linezolid, 600 mg/day x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Linezolid 600 mg/Twice Daily</title>
            <description>Linezolid 600 mg q12h x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) Adjusted for Free Drug Concentrations/Minimum Inhibitory Concentration (MIC)</title>
          <description>Area Under the Curve 0-12 (AUC 0-12) Adjusted for Free Drug Concentrations/Minimum Inhibitory Concentration (MIC) and AUC 0-24/MIC</description>
          <population>Twenty-nine patients underwent pharmacodynamic (PD) sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
          <units>ug/h/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-12/MIC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306.7" lower_limit="229.3" upper_limit="405.2"/>
                    <measurement group_id="O2" value="107.8" lower_limit="63.4" upper_limit="126.3"/>
                    <measurement group_id="O3" value="121.6" lower_limit="79.8" upper_limit="141.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-24/MIC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344.6" lower_limit="249.4" upper_limit="449.2"/>
                    <measurement group_id="O2" value="116.2" lower_limit="71.0" upper_limit="138.4"/>
                    <measurement group_id="O3" value="243.2" lower_limit="159.7" upper_limit="283.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Dosing Interval Above Minimum Inhibitory Concentration (MIC)</title>
        <description>Determined by linear extrapolation of concentration-versus-time curve to intersection with MIC.</description>
        <time_frame>Day 5 (7 time points)</time_frame>
        <population>Twenty-nine patients underwent pharmacodynamic (PD) sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Isoniazid (INH) 300 mg/Day</title>
            <description>Isoniazid (INH) 300 mg/day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Linezolid 600 mg/Once Daily</title>
            <description>Linezolid 600 mg/day x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Linezolid 600 mg/Twice Daily</title>
            <description>Linezolid 600 mg q12h x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Dosing Interval Above Minimum Inhibitory Concentration (MIC)</title>
          <description>Determined by linear extrapolation of concentration-versus-time curve to intersection with MIC.</description>
          <population>Twenty-nine patients underwent pharmacodynamic (PD) sampling after receiving 5 daily doses of study drug. One subject in the linezolid twice daily arm withdrew from the study after randomization before receiving any doses of study drug.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" lower_limit="76.4" upper_limit="100"/>
                    <measurement group_id="O2" value="62.8" lower_limit="54.6" upper_limit="77.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from February 2004 through October 2007.</time_frame>
      <desc>Patients reported adverse events at scheduled or unscheduled visits. Adverse event forms were completed by medical officers on site.</desc>
      <group_list>
        <group group_id="E1">
          <title>Gatifloxacin 400 mg/Day</title>
          <description>Gatifloxacin 400 mg/day x 7 days</description>
        </group>
        <group group_id="E2">
          <title>Levofloxacin 1000 mg/Day</title>
          <description>Levofloxacin 1000 mg/day x 7days</description>
        </group>
        <group group_id="E3">
          <title>Linezolid 600 mg / Once Daily</title>
          <description>Linezolid 600 mg/once daily x 7days</description>
        </group>
        <group group_id="E4">
          <title>Linezolid 600 mg / Twice Daily</title>
          <description>Linezolid 600 mg twice daily x 7 days</description>
        </group>
        <group group_id="E5">
          <title>Moxifloxacin 400 mg/Day</title>
          <description>Moxifloxacin 400 mg/day x 7 days</description>
        </group>
        <group group_id="E6">
          <title>Isoniazid (INH) 300 mg/Day</title>
          <description>Isoniazid (INH) 300 mg/day x 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Monocytes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hematocrit Decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hemoglobin Decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intestinal Ancyclostomiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intestinal Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intestinal Strongyloidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lumbar Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in Both Shoulders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rales (or Crackles)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="13" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E6" events="17" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ronchi</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The small sample size had limited power to detect small differences in EBA between study arms even though we enrolled patients with smear-positive TB and high sputum bacillary burden to improve chances of detecting differences between treatment arms.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John L. Johnson, M.D.</name_or_title>
      <organization>Case Western Reserve University, Tuberculosis Research Unit</organization>
      <phone>(216) 368-1949</phone>
      <email>jlj@case.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

